Tue, February 20, 2018
Fri, February 16, 2018
Thu, February 15, 2018
Wed, February 14, 2018
Tue, February 13, 2018
Mon, February 12, 2018
Fri, February 9, 2018
Thu, February 8, 2018
Wed, February 7, 2018
Tue, February 6, 2018
Mon, February 5, 2018
Fri, February 2, 2018

David Lebovitz Maintained (ALNY) at Hold with Decreased Target to $118 on, Feb 9th, 2018


//stocks-investing.news-articles.net/content/201 .. ith-decreased-target-to-118-on-feb-9th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $128 to $118 on, Feb 9th, 2018.

David has made no other calls on ALNY in the last 4 months.



There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $135 on, Thursday, January 25th, 2018


These are the ratings of the 5 analyists that currently disagree with David


  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy on, Thursday, November 9th, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $158 on, Wednesday, November 8th, 2017
  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $220 on, Wednesday, November 8th, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $151 on, Friday, November 3rd, 2017
  • Rahul Jasuja of "FBR Capital" Maintained at Strong Buy with Increased Target to $240 on, Thursday, November 2nd, 2017

Publication Contributing Sources